Drug Shortage Report for TEVA-TOBRAMYCIN
| Report ID | 227495 |
| Drug Identification Number | 02389622 |
| Brand name | TEVA-TOBRAMYCIN |
| Common or Proper name | TOBRAMYCIN 300mg/5ml |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | TOBRAMYCIN |
| Strength(s) | 60MG |
| Dosage form(s) | SOLUTION |
| Route of administration | INHALATION INHALATION |
| Packaging size | 56 |
| ATC code | J01GB |
| ATC description | AMINOGLYCOSIDE ANTIBACTERIALS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2024-05-08 |
| Estimated end date | 2025-06-10 |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2025-04-24 |
| Company comments | |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.